Registered Attendees
Registered Attendees
Print This PageRegistered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
Close Window
Eldorado Hotel & Spa Floorplan
This meeting took place in 2013
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Meeting Details
Epigenetic Marks and Cancer Drugs (C8)
Organizer(s) Ali Shilatifard
March 20 - March 25, 2013
Eldorado Hotel & Spa • Santa Fe, New Mexico USA
Abstract Deadline: November 19, 2012
Late Abstract Deadline: December 21, 2012
Scholarship Deadline: November 19, 2012
Early Registration Deadline: January 22, 2013
Sponsored by AVEO Oncology, Celgene Corporation, Genentech, Inc. and H3 Biomedicine Inc.
CME Information
Summary of Meeting:
To regulate the precise pattern of gene expression during development, eukaryotic cells have evolved to have multifaceted transcriptional machineries and chromatin states. The DNA within the eukaryotic nucleus is found in complex with histone proteins to form nucleosomes, the basic unit of chromatin. Detailed structural studies demonstrated that the N-terminal tails of each of the histones protrude outward beyond the gyres of DNA and can be posttranslationally modified. The modifications of histone tails could provide a landing pad for a diverse array of transcription factors, chromatin remodelers, and DNA-interacting proteins to regulate gene expression. Translocations and/or mutations in chromatin-modifying machineries that perturb the timing and/or pattern of gene expression can result in the pathogenesis of human diseases including cancer. Recent studies demonstrate that the misregulation of several of the histone-modifying enzymes can contribute to changes in the epigenetic state leading to disease development. Therefore, both the scientific and the pharmaceutical communities have concentrated on identifying the molecular function for many of the histone-modifying machineries and are in the process of developing small molecular inhibitors of their activities in the hope of their use for targeted therapeutics of cancer. This Keystone Symposia meeting on Epigenetic Marks and Cancer Drugs serves as a much-needed platform for bringing both the scientific and the pharmaceutical communities together to discuss recent advances in this very exciting area.
CME Information
To regulate the precise pattern of gene expression during development, eukaryotic cells have evolved to have multifaceted transcriptional machineries and chromatin states. The DNA within the eukaryotic nucleus is found in complex with histone proteins to form nucleosomes, the basic unit of chromatin. Detailed structural studies demonstrated that the N-terminal tails of each of the histones protrude outward beyond the gyres of DNA and can be posttranslationally modified. The modifications of histone tails could provide a landing pad for a diverse array of transcription factors, chromatin remodelers, and DNA-interacting proteins to regulate gene expression. Translocations and/or mutations in chromatin-modifying machineries that perturb the timing and/or pattern of gene expression can result in the pathogenesis of human diseases including cancer. Recent studies demonstrate that the misregulation of several of the histone-modifying enzymes can contribute to changes in the epigenetic state leading to disease development. Therefore, both the scientific and the pharmaceutical communities have concentrated on identifying the molecular function for many of the histone-modifying machineries and are in the process of developing small molecular inhibitors of their activities in the hope of their use for targeted therapeutics of cancer. This Keystone Symposia meeting on Epigenetic Marks and Cancer Drugs serves as a much-needed platform for bringing both the scientific and the pharmaceutical communities together to discuss recent advances in this very exciting area.
Conference Program Print | View meeting in 12 hr (am/pm) time
WEDNESDAY, MARCH 20
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
Stuart L. Schreiber,
HHMI/Harvard University, USA
Linking Genetic Features of Human Cancers and Histone-Modifying Enzymes for Future Cancer Therapies
Linking Genetic Features of Human Cancers and Histone-Modifying Enzymes for Future Cancer Therapies
09:00—11:00
Chromosomes, Chromatin and Transcription I
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
B. Franklin Pugh,
Pennsylvania State University, USA
Genome-Wide Interplay between Chromatin and the Transcription Machinery
Genome-Wide Interplay between Chromatin and the Transcription Machinery
Patrick Cramer,
University of Munich (LMU), Germany
New Insights into the Mechanisms of Transcription and its Regulation
New Insights into the Mechanisms of Transcription and its Regulation
Siavash K. Kurdistani,
University of California, Los Angeles, USA
Short Talk: Regulation of Intracellular pH by Histone Acetylation
Short Talk: Regulation of Intracellular pH by Histone Acetylation
Alejandro Vaquero,
Bellvitge Institute for Biomedical Research, Spain
Short Talk: SirT2 Regulates Cell Cycle Progression and Genome Stability by Modulating Mitotic Deposition of H4K20 Methylation
Short Talk: SirT2 Regulates Cell Cycle Progression and Genome Stability by Modulating Mitotic Deposition of H4K20 Methylation
14:30—16:30
Workshop 1
*
Mary Ann Osley,
University of New Mexico School of Medicine, USA
Masami Horikoshi,
University of Tokyo, Japan
“Modification Web” and “Signal Router” Theories on Histone Modification System and their Application to Development of Cancer Drugs
“Modification Web” and “Signal Router” Theories on Histone Modification System and their Application to Development of Cancer Drugs
Cigall Kadoch,
Stanford University School of Medicine, USA
Reversible Disruption of mSWI/SNF-Like BAF Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma
Reversible Disruption of mSWI/SNF-Like BAF Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma
Gary Hon,
University of California, San Diego, USA
Whole Genome Bisulfite Sequencing Reveals Tissue-Specific DNA Methylation in a Normal Mouse
Whole Genome Bisulfite Sequencing Reveals Tissue-Specific DNA Methylation in a Normal Mouse
Tal H. Salz,
University of Florida, USA
hSET1 Regulates the Canonical Wnt-Signaling Pathway and Plays a Role in Colorectal Cancer
hSET1 Regulates the Canonical Wnt-Signaling Pathway and Plays a Role in Colorectal Cancer
Eleni Maniati,
Queen Mary University of London, UK
Functional Effect of Aberrant Mll2/3 Gene Expression in Pancreatic Cancer
Functional Effect of Aberrant Mll2/3 Gene Expression in Pancreatic Cancer
Cheng-Fu Kao,
Academia Sinica, Taiwan
H2B Monoubiquitylation Regulates the Replication Stress Response
H2B Monoubiquitylation Regulates the Replication Stress Response
17:00—19:00
Chromosomes, Chromatin and Transcription II
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
Richard A. Young,
Whitehead Institute for Biomedical Research, USA
Connecting Transcription, Chromatin and Cancer
Connecting Transcription, Chromatin and Cancer
Shiv I. S. Grewal,
NCI, National Institutes of Health, USA
RNAi as an Adaptive Response Mechanism to Reprogram the Genome in Response to Growth and Developmental Signals
RNAi as an Adaptive Response Mechanism to Reprogram the Genome in Response to Growth and Developmental Signals
Anne Schaefer,
Mount Sinai School of Medicine, USA
Short Talk: PRC2 Governs Adult Neuron Specification and Function
Short Talk: PRC2 Governs Adult Neuron Specification and Function
Johnathan R. Whetstine,
Massachusetts General Hospital, USA
Short Talk: Looking at Cancer through the Eyes of Histone Demethylases
Short Talk: Looking at Cancer through the Eyes of Histone Demethylases
Charles Lin,
Dana-Farber Cancer Institute, USA
Short Talk: Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Short Talk: Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
08:00—11:00
Polycomb and Trithorax in Gene Expression and Cancer
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Shiv I. S. Grewal,
NCI, National Institutes of Health, USA
Ali Shilatifard,
Stowers Institute for Medical Research, USA
Chromatin Modifications, Transcriptional Elongation Control and Childhood Leukemia
Chromatin Modifications, Transcriptional Elongation Control and Childhood Leukemia
Danny F. Reinberg,
HHMI/New York University, USA
Polycomb Complexes
Polycomb Complexes
Jürg Müller,
Max Planck Institute of Biochemistry, Germany
Molecular Mechanisms of the Polycomb System
Molecular Mechanisms of the Polycomb System
Peter Verrijzer,
Erasmus University Medical Center, Netherlands
Antagonism between Polycomb and Trithorax in Development and Disease
Antagonism between Polycomb and Trithorax in Development and Disease
Kami Ahmad,
Harvard Medical School, USA
Short Talk: The Chromatin Configuration of Polycomb Response Elements (PREs) Define Epigenetic States
Short Talk: The Chromatin Configuration of Polycomb Response Elements (PREs) Define Epigenetic States
Francois Fuks,
University of Brussels, Belgium
Short Talk: TET Proteins Regulate GlcNAcylation and H3K4 Methylation through OGT and SET1/COMPASS
Short Talk: TET Proteins Regulate GlcNAcylation and H3K4 Methylation through OGT and SET1/COMPASS
Zhiguo Zhang,
Mayo Clinic, USA
Short Talk: Histone Modifications Regulate DNA Replication Coupled Nucleosome Assembly
Short Talk: Histone Modifications Regulate DNA Replication Coupled Nucleosome Assembly
17:00—19:00
Histone Marks in Development and Cancer
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
Thomas Jenuwein,
Max Planck Institute of Immunobiology and Epigenetics, Germany
Making and Breaking Heterochromatin
Making and Breaking Heterochromatin
Tony Kouzarides,
University of Cambridge, UK
Chromatin Modification Pathways and their Role in Cancer
Chromatin Modification Pathways and their Role in Cancer
Alexander (Sasha) Tarakhovsky,
Rockefeller University, USA
Ezh2, Histone Methylation and Prostate Cancer
Ezh2, Histone Methylation and Prostate Cancer
Shelley L. Berger,
University of Pennsylvania, USA
Profound Chromatin Changes in Eukaryotic Senescence and Aging
Profound Chromatin Changes in Eukaryotic Senescence and Aging
Mary Ann Osley,
University of New Mexico School of Medicine, USA
Short Talk: The Histone Modification Landscape of Quiescent Yeast Cells Formed during Chronological Aging
Short Talk: The Histone Modification Landscape of Quiescent Yeast Cells Formed during Chronological Aging
08:00—11:00
DNA Methylation in Development and Cancer
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
B. Franklin Pugh,
Pennsylvania State University, USA
Yi Zhang,
HHMI/Harvard Medical School, Children's Hospital Boston, USA
Role of Tet1-Mediated 5mC Oxidation in PGC Reprogramming and Meiosis
Role of Tet1-Mediated 5mC Oxidation in PGC Reprogramming and Meiosis
Peter A. Jones,
University of Southern California, USA
DNA Methylation and Cancer Therapy
DNA Methylation and Cancer Therapy
Jean-Pierre Issa,
Temple University School of Medicine, USA
Reprogramming of the Cancer Phenotype by Epigenetic Drugs in Patients with Myeloid Leukemias
Reprogramming of the Cancer Phenotype by Epigenetic Drugs in Patients with Myeloid Leukemias
Roger A. Greenberg,
University of Pennsylvania Perelman School of Medicine, USA
Short Talk: Acetylation Determines Double-Strand Break Repair Choice and Response to PARP Inhibition
Short Talk: Acetylation Determines Double-Strand Break Repair Choice and Response to PARP Inhibition
Gregory David,
New York University School of Medicine, USA
Short Talk: Epigenetic Regulation of Inflammation Modulates KRas-Driven Pancreatic Cancer Progression
Short Talk: Epigenetic Regulation of Inflammation Modulates KRas-Driven Pancreatic Cancer Progression
Diana Hargreaves,
Stanford University, USA
Short Talk: BAF Complexes Cooperate with Topoisomerase II alpha to Decatenate DNA
Short Talk: BAF Complexes Cooperate with Topoisomerase II alpha to Decatenate DNA
Li-Jung Juan,
Academia Sinica, Taiwan
Short Talk: Mechanisms of DNA Demethylation Enzymes TET Family Proteins in Suppressing Tumor Malignancy
Short Talk: Mechanisms of DNA Demethylation Enzymes TET Family Proteins in Suppressing Tumor Malignancy
17:00—19:00
Enhancers and ncRNAs in Development and Cancer
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Peter Verrijzer,
Erasmus University Medical Center, Netherlands
Jeannie T. Lee,
Massachusetts General Hospital, USA
The Roles of Long Noncoding RNA in Epigenetic Regulation
The Roles of Long Noncoding RNA in Epigenetic Regulation
Robert Martienssen,
Cold Spring Harbor Laboratory, USA
Inheritance and Reprogramming of Heterochromatin with Small RNA
Inheritance and Reprogramming of Heterochromatin with Small RNA
Celso A. Espinoza,
Ludwig Institute for Cancer Research, USA
Short Talk: Architectural Studies of Intramolecular Interactions between Enhancers and Promoters via ChIP-HiC
Short Talk: Architectural Studies of Intramolecular Interactions between Enhancers and Promoters via ChIP-HiC
08:00—11:00
Myc, Transcriptional Regulation and Development
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Kapil N. Bhalla,
University of Kansas Medical Center, USA
Robert N. Eisenman,
Fred Hutchinson Cancer Research Center, USA
Cooperative Transcriptional Regulation of Metabolism Mediated by the Myc-Max/Mlx-Mondo Network
Cooperative Transcriptional Regulation of Metabolism Mediated by the Myc-Max/Mlx-Mondo Network
Michael D. Cole,
Dartmouth Medical School, USA
An Epigenetic Model for Myc-Mediated Repression
An Epigenetic Model for Myc-Mediated Repression
Bruno Amati,
Italian Institute of Technology, Italy
Epigenome and Transcriptome Regulation in Myc-Driven Tumors
Epigenome and Transcriptome Regulation in Myc-Driven Tumors
Lin-Feng Chen,
University of Illinois at Urbana-Champaign, USA
Short Talk: Brd4 Maintains Constitutively Active NF-kappaB in Cancer Cells by Binding to Acetylated RelA
Short Talk: Brd4 Maintains Constitutively Active NF-kappaB in Cancer Cells by Binding to Acetylated RelA
Junwei Shi,
Cold Spring Harbor Laboratory, USA
Short Talk: Collaboration between the BAF Complex and Brd4 Maintains Myc Expression in Leukemia
Short Talk: Collaboration between the BAF Complex and Brd4 Maintains Myc Expression in Leukemia
Katherine A. Jones,
The Salk Institute, USA
Short Talk: Beta-Catenin Ubiquitylation and Release from LEF-1/TCF by a Novel alpha-Catenin:APC Complex
Short Talk: Beta-Catenin Ubiquitylation and Release from LEF-1/TCF by a Novel alpha-Catenin:APC Complex
14:30—16:30
Workshop 2
*
Roger A. Greenberg,
University of Pennsylvania Perelman School of Medicine, USA
Klaas Kok,
University Medical Center Groningen, Netherlands
The Impact of SETD2-Inactivating Mutations and Loss of H3K36 Trimethylation on Gene Expression in Clear Cell Renal Cell Carcinoma Progenitor Cells
The Impact of SETD2-Inactivating Mutations and Loss of H3K36 Trimethylation on Gene Expression in Clear Cell Renal Cell Carcinoma Progenitor Cells
Hao A. Duong,
Harvard Medical School, USA
Temporal Coordination of Histone De-Acetylase and Methyl-Transferase in Circadian Transcriptional Repression
Temporal Coordination of Histone De-Acetylase and Methyl-Transferase in Circadian Transcriptional Repression
Seung Hyuk Choi,
The Salk Institute, USA
Role for alpha-Catenin in APC-Mediated Repression at Wnt Target Genes
Role for alpha-Catenin in APC-Mediated Repression at Wnt Target Genes
Emily A. Clough,
NIDDK, National Institutes of Health, USA
The H4K16 Histone Acetyltransferase Chameau Is a Putative Target of Doublesex
The H4K16 Histone Acetyltransferase Chameau Is a Putative Target of Doublesex
Anil K. Panigrahi,
Baylor College of Medicine, USA
Dissecting the Role of H3K79 Methylation in Transcription Elongation and Leukemia
Dissecting the Role of H3K79 Methylation in Transcription Elongation and Leukemia
17:00—19:15
Transcription, Chromatin and Epigenetics in Cancer Therapy
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting
*
Robert N. Eisenman,
Fred Hutchinson Cancer Research Center, USA
Laurie A. Boyer,
Massachusetts Institute of Technology, USA
Molecular Analysis of Tissue Specific Programs in the Cardiac Lineage
Molecular Analysis of Tissue Specific Programs in the Cardiac Lineage
Robert J. Gould,
Epizyme, Inc., USA
Drugging the Human Methylome: Discovery and Characterization of Inhibitors of Protein Methyltransferases for the Treatment of Genetically Defined Cancers
Drugging the Human Methylome: Discovery and Characterization of Inhibitors of Protein Methyltransferases for the Treatment of Genetically Defined Cancers
Patrick Trojer,
Constellation Pharmaceuticals, USA
Targeting Histone Lysine Methylation in Cancer
Targeting Histone Lysine Methylation in Cancer
Marie Classon,
Genentech, Inc., USA
Short Talk: Chromatin Modifications and the Establishment of Drug-Tolerance
Short Talk: Chromatin Modifications and the Establishment of Drug-Tolerance
Kapil N. Bhalla,
University of Kansas Medical Center, USA
Short Talk: Highly Effective Combination of LSD1 Antagonist SP-2509 and Pan-HDAC Inhibitor Against Human AML Cells
Short Talk: Highly Effective Combination of LSD1 Antagonist SP-2509 and Pan-HDAC Inhibitor Against Human AML Cells
*Session Chair †Speaker invited, not yet responded.
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge additional support for this conference from:
|
|
|
|
|
|
We gratefully acknowledge support for this conference from:
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Melissa Carrera, Assistant
Director of Development, Email: MelissaC@keystonesymposia.org, Phone:+1 970-262-2679 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
